Prostate cancer: new therapies in the pipeline?
Cancer of the prostate gland is the highest unavoidable cause of cancer mortality in men. The recent identification and characterisation of genes specifically expressed in prostate cancer helps us to understand its molecular basis and should offer new therapeutic avenues to combat this disease.
Hurlstone
A
A
Beatson Institute for Cancer Research, CRC Beatson Laboratories, Bearsden, Glasgow, UK. d.black@udcf.gla.ac.uk
Black
D M
DM
D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000502:physiology*; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000502:physiology*; D058851:GPI-Linked Proteins; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000502:physiology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000502:physiology*; D015513:Oncogene Proteins / Q000235:genetics / Q000502:physiology*; D020648:Peptide Elongation Factor 1; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C094814:EEF1A1 protein, human; D058851:GPI-Linked Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D015513:Oncogene Proteins; C110843:PSCA protein, human; D020648:Peptide Elongation Factor 1